Comparison of Blood Flow in the Arteriae Uterinae in Ovarian Stimulation Cycles

Comparison of Blood Flow in the Arteriae Uterinae in Ovarian Stimulation Cycles for IVF/ICSI, in Hormonal Replacement Cycles and Natural Cycles for Frozen Embryo Transfer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03887728

Enrollment

124

Registered

2019-03-25

Start date

2019-04-23

Completion date

2020-12-14

Last updated

2021-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Receptivity

Keywords

progesterone, endometrium, blood flow, estradiol

Brief summary

This study will measure the blood flow in the aa. uterinae in women, undergoing firstly ovarian stimulation for In-Vitro Fertilization (IVF) / Intracytoplasmic sperm injection (ICSI), in Hormonal Replacement cycles (HRT) and Natural cycles (NC) for Frozen Embryo Transfer (FET)

Detailed description

To evaluate the influence of ovarian stimulation on the blood flow in the arteriae uterinae as well as whether there is an influence of the type of endometrial preparation for FET with either hormonal replacement therapy or natural cycle on the blood flow of the arteria uterina left / right

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

* Patients who undergo ovarian stimulation in a Gonadotropin-Releasing-Hormone (GnRH)-antagonist protocol for IVF / ICSI * Patients who have vitrified embryo(s) * Preparation for FET either in HRT or NC cycle

Exclusion criteria

* Poor responder according to Bologna criteria (Ferraretti et al.) as follows: * At least two of the following three features must be present: * (i) Advanced maternal age (≥40 years) or any other risk factor for poor ovarian reserve (POR); * (ii) A previous POR (≤3 oocytes with a conventional stimulation protocol); * (iii) An abnormal ovarian reserve test (i.e. antral follicle count (AFC) 5-7 follicles or anti-mullerian hormone (AMH) 0.5 -1.1 ng/ml). * Uterine surgery for removal of fibroids (hysteroscopic, laparoscopic) or removal of uterine septum * Endometriosis * Asherman-Syndrome * Previous cytotoxic treatment * Previous radiation of the uterus / adnexal region * Known hypertension * Intake of Aspirin or similar medication which might influence the blood flow * Status after tubal ligation * Status after surgery in the adnexal region on 1 side

Design outcomes

Primary

Measure	Time frame	Description
Difference in the blood flow, calculated as Pulsatility Index (PI) and Resistance Index (RI), between the HRT- and the NC-FET cycles	1 day	On the day of progesterone administration / progesterone rise. Quantitative continuous variable

Secondary

Measure	Time frame	Description
Continuous quantitative variable measured as the differences between average PI value	1 day	On the day of cycle start and the day of ovulation induction. Continuous quantitative variable measured in millimeters (mm)
Continuous quantitative variable measured as the differences between average RI value	2 days	On the day of cycle start and the day of ovulation induction
Thickness of the lining	1 day	Continuous quantitative variable measured in millimeters (mm)
Number of days of estradiol exposure	1 day	Before the embryo transfer

Countries

United Arab Emirates

Outcome results